Thanks to our correspondent Karlos, who sent us this nice video clip of an old Eddie Torres instructional DVD. I get a lot of questions about timing and clave - and of course, the main discussion of dancing On2/On1. Here is a great find, one of the best I've seen, on what it is to dance on clave.

This instruction specifically shows you how the 'tumbao' or 'el vacio' hooks into the basic salsa step. Specifically, watch how when those parts of the beat match the parts where Eddie in the video breaks forward and back.

Of course, that is all I will say (to reduce the nasty-grams about On2). Anyways, a video is worth ten-thousand words.

Adobe Flash Player is required to view this feature. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Original Article Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin, M.D., Ph.D., Vanna Chiarion-Sileni, M.D., Rene Gonzalez, M.D., Jean Jacques Grob, M.D., C. Lance Cowey, M.D., Christopher D.

Lao, M. Air Moon Safari Flac Rapidshare Files. D., M.P.H., Dirk Schadendorf, M.D., Reinhard Dummer, M.D., Michael Smylie, M.D., Piotr Rutkowski, M.D., Ph.D., Pier F. Ferrucci, M.D., Andrew Hill, M.D., John Wagstaff, M.D., Matteo S. Carlino, M.D., John B. Haanen, M.D., Michele Maio, M.D., Ph.D., Ivan Marquez-Rodas, M.D., Ph.D., Grant A. McArthur, M.D., Paolo A. Ascierto, M.D., Georgina V.

SALSA DANCE TIMING AND STYLE - NEW YORK ON 2 AND THE OTHERS - Some articles on the timing and style of New York ON 2 mambo, and how it. Apr 27, 2017. Eddie Torres Timing Cd. Za: Sitemap 9. El Camino Hacia La Riqueza - Estrategias De Exito Para El Emprendedor, Brian Tracy. Frontiers of Engineering - Reports on Leading- Edge Engineering from the 2. Symposium, National Academy of Engineering, National Academies.

Long, M.D., Margaret K. Callahan, M.D., Ph.D., Michael A. Postow, M.D., Kenneth Grossmann, M.D., Mario Sznol, M.D., Brigitte Dreno, M.D., Lars Bastholt, M.D., Arvin Yang, M.D., Ph.D., Linda M. Rollin, Ph.D., Christine Horak, Ph.D., F. Stephen Hodi, M.D., and Jedd D. Wolchok, M.D., Ph.D. N Engl J Med 2015; 373:23-34 DOI: 10.1056/NEJMoa1504030.

Results The median progression-free survival was 11.5 months (95% confidence interval [CI], 8.9 to 16.7) with nivolumab plus ipilimumab, as compared with 2.9 months (95% CI, 2.8 to 3.4) with ipilimumab (hazard ratio for death or disease progression, 0.42; 99.5% CI, 0.31 to 0.57; P. Figure 1 Progression-free Survival. Panel A shows the Kaplan–Meier curves for progression-free survival in the intention-to-treat population. Patients were followed for a minimum of 9 months. The median progression-free survival was 6.9 months (95% CI, 4.3 to 9.5) in the nivolumab group, 11.5 months (95% CI, 8.9 to 16.7) in the nivolumab-plus-ipilimumab group, and 2.9 months (95% CI, 2.8 to 3.4) in the ipilimumab group.

Significantly longer progression-free survival was observed in the nivolumab-plus-ipilimumab group than in the ipilimumab group (hazard ratio for death or disease progression, 0.42; 99. Download Stardock Fences Portable Buildings. 5% CI, 0.31 to 0.57; P. Figure 2 Tumor-Burden Change in Target Lesions. The waterfall plots show the maximum change from baseline in the sum of the reference diameters of the target lesion in patients receiving nivolumab (Panel A), nivolumab plus ipilimumab (Panel B), or ipilimumab (Panel C).